ArticleBone marrow transplantation2020
The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.
Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.The Cochrane database of systematic reviews · 2023Pooled it
- The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.Bone marrow transplantation · 2026Article
- Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers.Frontiers in oncology · 2026Article
- Quantifying the Clinical and Economic Burden of Graft-Versus-Host Disease Following Allogeneic Haematopoietic Stem Cell Transplantation in England: A Retrospective Cohort Study.Advances in therapy · 2025Article
- Article
- Haematopoietic stem cell transplantation for children and young people: is there a role for prehabilitation? A scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Establishing a national pediatric stem cell transplantation registry in Iran addressing implementation and data quality challenges.Scientific reports · 2025Article
- Critical care illness in allogeneic hematopoietic stem-cell transplantation recipients with chronic graft versus host disease.Critical care (London, England) · 2025Article
- Natural killer cells adopt an activated and decidual-like phenotype after autologous hematopoietic stem cell transplantation in children with cancer.Communications medicine · 2025Article
- Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT.Bone marrow transplantation · 2025Article
- Low-dose anti-thymocyte globulin combined with low-dose post-transplant cyclophosphamide: a novel approach to prevent graft-versus-host disease in haploidentical stem cell transplantation.Therapeutic advances in hematology · 2025Article
- The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival After Chemotherapy and Allogeneic Transplantation in Mice.Annals of transplantation · 2024Article
- Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.Bone marrow transplantation · 2024Article
- Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT.Blood advances · 2024Article
- ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.Bone marrow transplantation · 2024Article
- Parents' experiences of living with a child with cancer undergoing hematopoietic stem cell transplantation: a qualitative content analysis study.Frontiers in psychology · 2024Article
- Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia.Annals of hematology · 2024Article
- Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.Bone marrow transplantation · 2023Article
- Predictors of post traumatic growth in allogeneic hematopoietic stem cell transplantation survivors: a cross-sectional survey.BMC psychology · 2023Article
- Sulfated Polysaccharide Regulates the Homing of HSPCs in a BMP-2-Triggered In Vivo Osteo-Organoid.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year's analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.